KalVista Pharmaceuticals, Inc.
KALV
$11.85
$0.100.85%
NASDAQ
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -0.87% | 26.18% | |||
| Gross Profit | 9.85% | -26.18% | |||
| SG&A Expenses | 14.16% | 28.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.82% | 28.16% | |||
| Operating Income | -7.23% | -28.16% | |||
| Income Before Tax | -9.15% | -19.92% | |||
| Income Tax Expenses | 352.28% | -120.13% | |||
| Earnings from Continuing Operations | -15.07% | -7.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.07% | -7.66% | |||
| EBIT | -7.23% | -28.16% | |||
| EBITDA | -7.28% | -28.23% | |||
| EPS Basic | -14.10% | -6.85% | |||
| Normalized Basic EPS | -8.57% | -19.24% | |||
| EPS Diluted | -14.10% | -6.85% | |||
| Normalized Diluted EPS | -8.57% | -19.24% | |||
| Average Basic Shares Outstanding | 0.85% | 0.77% | |||
| Average Diluted Shares Outstanding | 0.85% | 0.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||